Announcements Trials
Browse Landscape

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 1Dwarfism, Pituitary 1Diabetes Mellitus, Type 2 1

Interventions

Specimen Handling 5Surveys and Questionnaires 4Observation 4Blood Specimen Collection 4Drug Therapy 3Chemoradiotherapy 3Surgical Procedures, Operative 2Electrocardiography 2Echocardiography 2Capecitabine 2Biopsy 2trifluridine tipiracil drug combination 1tegafur-gimeracil-oteracil 1somapacitan 1olverembatinib 1lorlatinib 1lenvatinib 1gallium 68 PSMA-11 1brexucabtagene autoleucel 1axicabtagene ciloleucel 1Zoledronic Acid 1Tumor Burden 1Telemedicine 1Tegafur 1Stents 1Spermine Synthase 1S 1 (combination) 1Robotic Surgical Procedures 1Rituximab 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Enrolling by invitation × Observational × somapacitan × Clear all
NCT06709040 2026-04-06

A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters

Novo Nordisk A/S

Enrolling by invitation
500 enrolled
Endocrine

Diabetes Mellitus, Type 2, Dwarfism, Pituitary, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡